All News
RheumNow's expanded coverage of the #ACR2019 annual meeting is sponsored in part by Novartis. All content chosen by RheumNow and its faculty.
Dr. John Cush RheumNow ( View Tweet)
#ACR19 Review Course — Update in RA Therapy 2019 — Dr. Michael Weinblatt.
My notes in thread ⬇️⬇️⬇️
Dr. Paul Sufka psufka ( View Tweet)
From CORRONA registry- TCZ plus MTX similar drug survival compared to TBF plus MTX in TNFIR https://t.co/iDdYIoBlWo @RheumNow #ACR19
Links:
Dr. Arthur Lau ArthurRheum ( View Tweet)
OLE data shows Tx with Sarilumab improved likelihood of glucocorticoid dose reduction with 16% able to discontinue @RheumNow #ACR19 https://t.co/YWetjp5Rlp
Dr. Arthur Lau ArthurRheum ( View Tweet)
Should we measure vit D in all pregnant women with SLE? As in general population low vitamin D increased miscarriage and preterm births. Weird as so did high vitamin D. Abstr 2531 #ACR #ACR19 @RheumNow #SLE #sle https://t.co/Mwb3WoCyBA
Janet Pope Janetbirdope ( View Tweet)
@Drbeckyg featured in the ACR Rheumatology Round-up!! Makes us think about how we might engage patients better in their disease assessment...
#ACR19 ABST1366 @RheumNow https://t.co/47DfV7RH1s https://t.co/MZarkQkDdb
Links:
David Liew drdavidliew ( View Tweet)
Ken Cai, Aussie presenting NZ research
#ACR19 @earlyara Abst2732 https://t.co/K7mltsR8q3
Dr Irwin Lim _connectedcare ( View Tweet)
Size of M protein, type & abnormal free light chain protein ratio allows prognostication for MGUS
#ACR19 @rheumnow 5T064
Dr Irwin Lim _connectedcare ( View Tweet)
What contributes to serious infections in RA? Higher inflammation and GC use, not bDMARD or tofacitinib use increased infectious risk
Bella Mehta et al. RMD Open 2019
#ACR19 @RheumNow
Kanika Monga, MD DrKanikaMonga ( View Tweet)
- Risk of bDMARD withdrawal higher for TNFi monotherapy
compared w/ cs/bDMARD combination
- If monotherapy necessary, etanercept should be
preferred over infliximab and adalimumab
Silvagni E et al. BMJ Open 2018 #ACR19 @RheumNow
Kanika Monga, MD DrKanikaMonga ( View Tweet)
RheumNow's expanded coverage of the #ACR2019 annual meeting is sponsored in part by Sanofi Genzyme and Regeneron. All content chosen by RheumNow and its faculty.
Dr. John Cush RheumNow ( View Tweet)
SLE uncommonly has ILD in clinical practice. 2% had ILD usually mild and non progressive abstr 1563 #ACR #ACR19 @RheumNow #SLE https://t.co/CWgdfEQZ27
Janet Pope Janetbirdope ( View Tweet)
Prednisone is associated with organ damage in SLE. Chicken or egg argument? Bad lupus gets more steroids and more damage AND steroids independently increase CV events and other damage ex OP and cataracts #ACR19 @RheumNow abstr 2562 #SLE https://t.co/onEII3OKhS
Janet Pope Janetbirdope ( View Tweet)
Abstract #1759 MTX did not demonstrate superior efficacy over placebo on pain and function at 3 and 12 months Erosive Hand OA (EHOA). MTX significantly reduced the progression of joint damage compared to placebo #ACR19 @RheumNow
Do you use MTX in EHOA?
Dr. Antoni Chan synovialjoints ( View Tweet)
A short piece I wrote for @RheumNow on classification criteria and their role in diagnosis / clinical practice
1. These are meant for research!
2. We use them for diagnosis anyway...
3. Remember their limitations when doing so!
@RheumNow
https://t.co/SSr28zkc0U https://t.co/EDzgWPIxXe
Mike Putman EBRheum ( View Tweet)
Great talk by Dr. Manzi for Year in Review!
See my recent podcast about SPIRIT-H2H. It shows that IXE > ADA for skin but NOT for joints.
@RheumNow #ACR19
https://t.co/FzY8O7KX1A
Mike Putman EBRheum ( View Tweet)
It's Dr. Paul Sufka @psufka talking about methotrexate and prednisone for Hand osteoarthritis https://t.co/jRwWgzVvPx #ACR19 @rheumnow
Philip Robinson philipcrobinson ( View Tweet)
This is an excellent review by @BolekBerqui on the use of social media. Great quote “We can think of the internet like the medical elevator” #ACR19 #ACRBest @RheumNow https://t.co/CNzVtrFgr2
Dr. Antoni Chan synovialjoints ( View Tweet)
BK virus bite Mia was not increased in CTD or drug use. Safe and reassuring and different from cornyviris which is increased with Rituximab but small study. Maybe underpowered #ACR19 @RheumNow abstr 2115 https://t.co/8z77Pxgp3E
Janet Pope Janetbirdope ( View Tweet)
#ACR19 Year in Review: Important trial in APLS this year demonstrating to me that DOACs should clearly not be used in this disease state.
Rate of stroke 19% in rivaroxaban vs. 3% in warfarin. @RheumNow https://t.co/YkXRg0J944
Mike Putman EBRheum ( View Tweet)
